GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL — Stella

Home/Non-hodgkin Lymphoma/

View on ClinicalTrials.gov

Recruiting

Back to Non-hodgkin Lymphoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Bing Xu, Xiamen, Fujian

Key details

Phase

Early testing

Sponsor

The First Affiliated Hospital of Xiamen University

Enrollment target

~45 participants

Started

April 2026

Primary completion

May 2026

Age range

18 Years – 70 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.